Company news
Fluoguide A/s (OMXSTO:FLUO) news
Fluoguide A/s news releases on 6ix. Latest, Oct 5, 2026: FluoGuide Enrolls First Patient in U.S. Phase 2 Trial of FG001 in High-Grade Glioma
Press releases & updates
FluoGuide Enrolls First Patient in U.S. Phase 2 Trial of FG001 in High-Grade Glioma
October 5, 2026
FluoGuide Enters Collaboration with Leica Microsystems, a World Leading Medical Technology Company
October 2, 2026
FluoGuide A/S publishes interim report for Q2 2026
August 25, 2026
Invitation to FluoGuide A/S live webcast on 25 August 2026
August 12, 2026
FluoGuide A/S publishes interim report for Q1 2026
May 27, 2026
Invitation to FluoGuide A/S live webcast on 27 May 2026
May 13, 2026
FluoGuide Receives FDA Fast Track Designation for FG001 in High-Grade Glioma
March 18, 2026
Notice of Annual General Meeting in FluoGuide A/S
March 10, 2026
FluoGuide A/S Publishes Annual Report For The Fiscal Year 2025
February 25, 2026
FluoGuide A/S Publishes Interim Report For Q4 2025
February 25, 2026
FDA Clears FluoGuide's IND for FG001 in High-Grade Glioma; U.S. Clinical Trial Remains on Track
February 20, 2026
Invitation to FluoGuide A/S (Nasdaq:FLUO) Live Webcast on 25 February 2026
February 19, 2026
FluoGuide Submits an IND for FG001, to Initiate First U.S. Registration Trial
January 21, 2026
FluoGuide updates IND submission timing for FG001 – trial initiation unaffected
December 19, 2025
FluoGuide A/S Publishes Interim Report Q3 2025
November 27, 2025
FluoGuide Signs Collaboration Agreement with ZEISS
November 25, 2025
Invitation to FluoGuide A/S (Nasdaq: FLUO) Webcast on 27 November 2025
November 24, 2025
FluoGuide Strengthens Leadership to Advance Clinical Program and Regulatory Approval Strategy
November 5, 2025
FluoGuide Convenes an Extraordinary General Meeting
November 5, 2025
FluoGuide A/S Issue Warrants to Board Members, Executive Management and Employees
November 3, 2025
FluoGuide A/S Completes Directed Share Issue of SEK 104 Million
November 3, 2025
FluoGuide A/S Intends to Carry Out a Directed Share Issue of Approximately SEK 100 Million
November 3, 2025
FluoGuide in Advanced Negotiations on Collaboration Agreement with a World Leading Medical Technology Company
October 28, 2025
FluoGuide Receives Positive FDA Feedback on FG001 in High-Grade Glioma
September 16, 2025
FluoGuide A/S Publishes Interim Report H1 2025
August 28, 2025
Invitation to FluoGuide A/S (Nasdaq:FLUO) Webcast on 28 August 2025
August 22, 2025
FluoGuide Enters Collaboration with Global MedTech Company Olympus
July 21, 2025
FG001 clinical data in High-Grade Glioma is now published in Neurosurgery
June 10, 2025